Novartis Ag (NVS) Asset Utilization Ratio (2009 - 2026)
Novartis Ag's (NVS) quarterly Asset Utilization Ratio came in at 0.57 in Q2 2026, down 24.47% year-over-year from 0.76 in Q2 2025, and down 4.11% quarter-over-quarter from 0.6 in Q1 2026.
Analysis
Novartis Ag (NVS) Asset Utilization Ratio (2009 - 2026) Analysis & Trends
Novartis Ag has disclosed Asset Utilization Ratio across 18 years of filings, most recently posting 0.57 for Q2 2026.
- In Q2 2026, Asset Utilization Ratio fell 24.47% year-over-year to 0.57; the TTM figure through Jun 2026 stood at 0.57 (down 24.47% YoY), while the FY2025 annual figure was 0.51, up 2.78% from the prior year.
- Asset Utilization Ratio came in at 0.57 for Q2 2026 at Novartis Ag, down from 0.6 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.76 in Q2 2025 to a low of 0.5 in Q1 2022.
- Average Asset Utilization Ratio over 5 years is 0.63, with a median of 0.61 recorded in 2026.
- Year-over-year, Asset Utilization Ratio gained 26.81% in 2024 and slipped 24.47% in 2026.
- Over 5 years, Asset Utilization Ratio stood at 0.57 in 2022, then advanced by 11.93% to 0.64 in 2023, then climbed by 12.9% to 0.72 in 2024, then slipped by 13.13% to 0.63 in 2025, then declined by 8.97% to 0.57 in 2026.
- Per Business Quant data, the three most recent Asset Utilization Ratio figures were 0.57 in Q2 2026, 0.6 in Q1 2026, and 0.63 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.43 Bn | 620.67 Bn | 17.26 Bn | 0.49 |
| 2 | AbbVie | 446.70 Bn | 440.13 Bn | 12.70 Bn | 0.47 |
| 3 | Merck | 358.22 Bn | 351.08 Bn | 12.21 Bn | 0.52 |
| 4 | Novartis Ag | 268.35 Bn | 260.66 Bn | 11.24 Bn | 0.57 |
| 5 | Pfizer | 156.81 Bn | 145.11 Bn | 10.94 Bn | 0.31 |
| 6 | Sanofi | 52.18 Bn | 44.80 Bn | 10.79 Bn | 0.36 |
| 7 | Revolution Medicines | 43.02 Bn | 43.02 Bn | - | - |
| 8 | Incyte | 24.83 Bn | 20.29 Bn | 1.57 Bn | 0.77 |
| 9 | United Therapeutics | 21.38 Bn | 18.72 Bn | 683.80 Mn | 0.45 |
| 10 | Neurocrine Biosciences | 15.89 Bn | 15.50 Bn | 935.80 Mn | 0.66 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.57 |
| Mar 31, 2026 | 0.60 |
| Dec 31, 2025 | 0.63 |
| Sep 30, 2025 | 0.74 |
| Jun 30, 2025 | 0.76 |
| Mar 31, 2025 | 0.75 |
| Dec 31, 2024 | 0.72 |
| Sep 30, 2024 | 0.71 |
| Jun 30, 2024 | 0.73 |
| Mar 31, 2024 | 0.71 |
| Dec 31, 2023 | 0.64 |
| Sep 30, 2023 | 0.59 |
| Jun 30, 2023 | 0.58 |
| Mar 31, 2023 | 0.57 |
| Dec 31, 2022 | 0.57 |
| Sep 30, 2022 | 0.51 |
| Jun 30, 2022 | 0.51 |
| Mar 31, 2022 | 0.50 |
| Dec 31, 2021 | 0.50 |
| Sep 30, 2021 | 0.51 |